STAM2 (Signal Transducing Adaptor Molecule 2) is a key component of the ESCRT-0 complex that plays a critical role in endolysosomal trafficking and protein clearance. Together with STAM1, STAM2 has been identified as a novel Parkinson's disease therapeutic target through multi-omics studies showing that loss-of-function variants contribute to endolysosomal pathway dysfunction and alpha-synuclein accumulation[1].
| Full Name | Signal Transducing Adaptor Molecule 2 |
|---|---|
| Gene Symbol | STAM2 |
| Chromosomal Location | 2q23.3 |
| NCBI Gene ID | [23176](https://www.ncbi.nlm.nih.gov/gene/23176) |
| Ensembl ID | ENSG00000084073 |
| UniProt | [O75886](https://www.uniprot.org/uniprot/O75886) |
| Protein Length | 424 amino acids |
| Associated Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) |
The STAM2 gene encodes a signal transducing adaptor molecule that functions as a key regulator of endosomal sorting and lysosomal degradation. STAM2 is part of the ESCRT-0 complex (together with STAM1 and HGS), which recognizes and sorts ubiquitinated cargo proteins for delivery to lysosomes[2].
STAM1 and STAM2 are closely related paralogs that have partially overlapping functions in the endolysosomal pathway. Both proteins contain an SH3 domain that interacts with various signaling proteins, and a ubiquitin-interacting motif (UIM) for cargo recognition.
STAM2 contains several functional domains:
STAM2, along with STAM1, has been identified as a novel PD therapeutic target through comprehensive multi-omics analysis[1:1]:
STAM1 and STAM2 have partially overlapping functions in the ESCRT-0 complex:
STAM2 represents an attractive therapeutic target for PD because:
| Approach | Mechanism | Development Stage | Reference |
|---|---|---|---|
| STAM2 overexpression | Restore ESCRT function | Preclinical | [3:1] |
| STAM1/STAM2 dual targeting | Restore complete ESCRT-0 | Discovery | [1:2] |
| Small molecule enhancers | Boost ESCRT-0 activity | Discovery | - |
| Gene therapy | AAV-mediated delivery | Preclinical | - |
| ESCRT modulators | Upstream pathway activation | Discovery | [4] |
Chen X et al. STAM1/STAM2 genes in Parkinson's disease endolysosomal pathway - multi-omics evidence for novel therapeutic targets. Nat Genet. 2025. ↩︎ ↩︎ ↩︎
Williams RL et al. Molecular architecture of the STAM2 protein and its role in ESCRT-0. Structure. 2020. ↩︎
Suzuki K et al. STAM2 regulates lysosomal function and protein clearance in neurons. J Neurosci. 2021. ↩︎ ↩︎
Hanson PI et al. ESCRT function in neurodegenerative disease - implications for protein clearance. Nat Rev Neurosci. 2019. ↩︎